Sepsis-induced cardiogenic shock: controversies and evidence gaps in diagnosis and management.

Sepsis often leads to vasoplegia and a hyperdynamic cardiac state, with treatment focused on restoring vascular tone. However, sepsis can also cause reversible myocardial dysfunction, particularly in the elderly with pre-existing heart conditions. The Surviving Sepsis Campaign Guidelines recommend using dobutamine with norepinephrine or epinephrine alone for patients with septic shock with cardiac dysfunction and persistent hypoperfusion despite adequate fluid resuscitation and stable blood pressure.

Synthesis of Azocine-Fused Indoles via Gold(I)-Catalyzed Cyclization of Azido-alkynes.

Herein, we report a gold(I)-catalyzed cascade cyclization of azido-alkynes bearing an enol ester moiety, leading to indole-fused eight-membered rings. This method allows for the one-step construction of indole and tetrahydroazocin-4-one via an α-imino gold carbene intermediate. The resulting scaffold would be useful for accessing natural products with an eight-membered ring-fused indole moiety.

Quality of Life and Oral Function in Patients With Jaw Defects Following Oral Tumour Surgery.

Objectives: To evaluate various oral functions in patients with jaw defects after oral tumour surgery and to clarify factors associated with their quality of life (QoL).

Background: In patients with jaw defects, oral function and QoL are severely impaired. No studies have evaluated oral functions of patients with jaw defects and examined their relationships with QoL.

Early eosinophilia after hematopoietic stem cell transplantation is associated with chronic graft-versus-host disease.

Background: This study aimed to evaluate whether an early elevation of absolute eosinophil count after allogeneic hematopoietic stem cell transplantation (allo-HSCT) was associated with the development of chronic graft-versus-host disease (cGVHD) in children and adolescents.

Methods: A total of 165 consecutive patients who received allo-HSCT were included in the study. Patients who had previously received allo-HSCT, relapsed or died before Day 100, and did not achieve engraftment, were excluded.